DEF 14C: ImmunityBio Boosts Authorized Shares for Future Funding

ImmunityBio, Inc. has increased its authorized common stock to 1.65 billion shares to secure future funding and meet existing commitments.

Summary

• ImmunityBio, Inc. increased its authorized shares of Common Stock from 1,350,000,000 to 1,650,000,000 shares.
• The Board of Directors approved this action on October 6, 2025, and stockholders representing approximately 66.0% of voting power approved it by written consent on October 7, 2025.
• The primary reason for the increase is to provide future funding for the Company's operations and to cover current, committed issuances of Common Stock and expected funding needs for at least the next 12 months.
• The amendment will become effective no earlier than twenty (20) calendar days after the mailing of the Information Statement, anticipated to be on or about November 10, 2025.
• No stockholder vote or proxy solicitation was required due to the majority written consent.

Sentiment

Score: 5

Explanation: Neutral. While necessary for future funding and operational continuity, the action carries a significant risk of dilution for existing shareholders, balancing the positive aspect of securing capital.

Positives

• Enhances financial flexibility for future capital raises.
• Ensures adequate authorized shares to cover current and committed issuances, avoiding potential contractual penalties.
• Aims to secure funding for operations for at least the next 12 months.

Negatives

• The sale and issuance of additional shares will result in substantial dilution for existing stockholders.
• Potential decline in stock price due to dilution, causing financial harm to existing stockholders.

Risks

• Dilution of existing stockholders upon the sale and issuance of additional shares.
• Potential decline in Common Stock price due to dilution.
• Contractual penalties if insufficient authorized shares are available to honor committed issuances.
• Uncertainty regarding the number of shares issuable upon conversion of convertible debt instruments, dependent on market price and interest rates.

Future Outlook

The increase in authorized shares is intended to cover all current, committed issuances of Common Stock and the Company's expected funding needs for at least the next 12 months.

Management Comments

• The Board determined to pursue stockholder action by majority written consent to reduce the costs and management time required for a special meeting of stockholders, and to implement the action in a timely manner.

Industry Context

Companies in the biotechnology and pharmaceutical sectors, especially those in development stages, frequently require significant capital for research, clinical trials, and commercialization. Increasing authorized shares is a common mechanism to facilitate future equity or convertible debt financing to sustain operations and advance product pipelines. This action aligns with typical capital-intensive strategies in the industry.

Corporate Governance

Related Party Transactions

• Patrick Soon-Shiong, M.D., FRCS (C), FACS, beneficially owns 68.94% of Common Stock, including shares held by entities he controls (Nant Capital, Cambridge Equities, NantMobile, NCSC, NantWorks, NantBio, California Capital, Chan Soon-Shiong Family Foundation).
• Nant Capital, LLC beneficially owns 31.49% of Common Stock.
• Cambridge Equities, LP beneficially owns 26.57% of Common Stock.
• California Capital Equity, LLC beneficially owns 10.81% of Common Stock.
• NantWorks, LLC beneficially owns 10.00% of Common Stock.
• All directors and executive officers as a group beneficially own 69.48% of Common Stock.

Stakeholder Impact

• Shareholders: Potential for significant dilution of existing stockholders' ownership percentage and potential decline in stock price.
• Company Operations: Improved ability to raise capital to fund ongoing operations, research, and development for at least the next 12 months.
• Creditors/Lenders: Provides assurance of available shares for conversion of convertible instruments, potentially facilitating future debt financing.

Next Steps

• The Certificate of Amendment will become effective no earlier than twenty (20) calendar days after the mailing of the Information Statement, anticipated to be on or about November 10, 2025.

Key Dates

Recommendation

The increase in authorized shares is a necessary corporate action to ensure the company's ability to raise capital for future operations and meet existing commitments. While it provides essential financial flexibility, the potential for significant dilution of existing shareholders is a notable negative. Investors should hold, acknowledging the long-term operational necessity balanced against the short-to-medium term dilution risk, and monitor future capital raising activities and their terms.

Keywords

ImmunityBio, IBRX, authorized shares, common stock, capital raise, dilution, SEC filing, corporate governance, financing, biotechnology, pharmaceutical